$4.22-0.05 (-1.17%)
TriSalus Life Sciences, Inc.
TriSalus Life Sciences, Inc. in the Healthcare sector is trading at $4.22 with a market capitalization of $195M. Wall Street consensus targets $9.00 (4 analysts), implying a +113.3% move over the next 12 months. The stock is currently 47% below its 52-week high of $7.95, remaining 11.7% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $8.90Mβ | $13.21Mβ | $11.57Mβ | $11.21Mβ | $9.17M |
| Gross Profit | $7.67Mβ | $11.44Mβ | $9.66Mβ | $9.41Mβ | $7.67M |
| Operating Income | -$8.41Mβ | -$3.27Mβ | -$9.01Mβ | -$7.33M | -$7.33M |
| Net Income | $1.54Mβ | -$9.75Mβ | -$10.81Mβ | -$8.29Mβ | -$10.38M |
TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in th...
QuidelOrtho (QDEL) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
TriSalus Life Sciences Inc (TLSI) navigates commercial growth and FDA delays while showcasing improved margins and robust clinical data.
TriSalus Life Sciences (NASDAQ:TLSI) reported slightly lower first-quarter revenue and reduced its full-year 2026 revenue outlook, citing disruption from a broad commercial reorganization and a delayed FDA review for its next-generation TriNav Advance device. President and Chief Executive Officer M
Moby summary of TriSalus Life Sciences, Inc.'s Q1 2026 earnings call
TriSalus Life Sciences, Inc. (TLSI) delivered earnings and revenue surprises of +12.50% and -15.25%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?